We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

52 hedge funds and large institutions have $58M invested in Calithera Biosciences, Inc in 2015 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 5 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 5

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

33% more funds holding

Funds holding: 3952 (+13)

60% less capital invested

Capital invested by funds: $143M → $58M (-$85.3M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $205K

Holders
52
Holders Change
+13
Holders Change %
+33.33%
% of All Funds
1.4%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
24
Increased
20
Reduced
5
Closed
11
Calls
Puts
$205K
Net Calls
-$205K
Net Calls Change
-$205K
Name Holding Trade Value Shares
Change
Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$19.7M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$19.2M +$6.48M +27,963 +26%
EC
3
EcoR1 Capital
California
$2.97M +$1.39M +6,000 +41%
NI
4
Numeric Investors
Massachusetts
$2.39M +$3.89M +16,767 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.99M +$189K +817 +6%
BFA
6
BlackRock Fund Advisors
California
$1.96M +$3.17M +13,694 New
CS
7
Candriam SCA
Luxembourg
$1.64M +$464K +2,000 +21%
BIT
8
BlackRock Institutional Trust
California
$1.1M +$1.78M +7,682 New
NLVP
9
New Leaf Venture Partners
New York
$970K -$4.87M -21,007 -76%
State Street
10
State Street
Massachusetts
$595K +$37.8K +163 +4%
Northern Trust
11
Northern Trust
Illinois
$580K +$1.62K +7 +0.2%
EMG
12
Ellington Management Group
Connecticut
$570K +$926K +3,994 New
Geode Capital Management
13
Geode Capital Management
Massachusetts
$384K +$32.7K +141 +6%
FAM
14
Fred Alger Management
New York
$373K +$359K +1,550 +146%
BIM
15
BlackRock Investment Management
Delaware
$303K +$491K +2,120 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$294K +$114K +492 +31%
Deutsche Bank
17
Deutsche Bank
Germany
$289K +$472K +2,038 +203,800%
TCIM
18
TIAA CREF Investment Management
New York
$279K +$279K +1,202 +160%
FSA
19
Franklin Street Advisors
North Carolina
$195K +$316K +1,363 New
Goldman Sachs
20
Goldman Sachs
New York
$168K +$273K +1,179 New
California State Teachers Retirement System (CalSTRS)
21
California State Teachers Retirement System (CalSTRS)
California
$144K +$66.3K +286 +39%
BC
22
Birchview Capital
Vermont
$141K +$228K +985 New
Charles Schwab
23
Charles Schwab
California
$136K +$89.3K +385 +68%
TC
24
TFS Capital
Pennsylvania
$122K +$199K +857 New
T. Rowe Price Associates
25
T. Rowe Price Associates
Maryland
$119K -$14.2M -61,228 -99%

CALA Hedge Fund Activity: Q2 2015 in Review

52 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q2 2015, worth a combined $58M — down 60% from $143M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CALA positions and 11 closed out — a net gain of 13 holders — while 20 added to existing stakes and 5 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $6.48M. The largest seller was T. Rowe Price Associates, cutting an estimated $14.2M.

  • 52 institutional investors held Calithera Biosciences, Inc (CALA) as of Q2 2015, up from 39 in Q1 2015.
  • Funds reported $58M of Calithera Biosciences, Inc stock for Q2 2015, down 60% quarter-over-quarter.
  • 24 funds opened new Calithera Biosciences, Inc positions in Q2 2015 and 11 closed out, a net change of +13 holders.
  • The largest Calithera Biosciences, Inc buyer in Q2 2015 was Fidelity Investments, an estimated $6.48M added.
  • The largest Calithera Biosciences, Inc seller in Q2 2015 was T. Rowe Price Associates, an estimated $14.2M sold.

Based on aggregated 13F filings for Q2 2015.